Literature DB >> 21320954

Visual field extent at 6 years of age in children who had high-risk prethreshold retinopathy of prematurity.

Graham E Quinn1, Velma Dobson, Robert J Hardy, Betty Tung, Earl A Palmer, William V Good.   

Abstract

OBJECTIVE: To compare monocular visual field extent at 6 years of age in eyes with high-risk prethreshold retinopathy of prematurity (ROP) randomized to early treatment (ET) with eyes that underwent conventional management (CM) and were treated at threshold or regressed without treatment.
METHODS: Subjects were 370 surviving study participants who developed high-risk prethreshold ROP and were enrolled in the Early Treatment for Retinopathy of Prematurity Study between October 1, 2000, and September 30, 2002. When the participants were 6 years of age, vision testers unaware of ROP status used white-sphere kinetic perimetry to measure visual field extent along the superotemporal, inferotemporal, inferonasal, and superonasal meridians.
RESULTS: The extent of the visual field was 0.1° to 3.7° larger in ET eyes when blind eyes were assigned a score of 0°. When data were examined from eyes of participants with 1 sighted ET eye and 1 sighted CM eye, ET eyes showed a small (1.3°-3.1°) reduction, which was statistically significant only along the superonasal meridian (P = .005). In bilaterally sighted children, visual field extent was not significantly reduced for high-risk type 1 ET eyes (-0.9° to 1.8°). However, in ET eyes with high-risk type 2 disease, visual field extent was significantly smaller compared with that of CM eyes (3.6°-8.7° superonasal field [P = .003]; inferonasal field [P < .001]).
CONCLUSION: Early treatment preserves peripheral vision, with only a small reduction of visual field extent. APPLICATION TO CLINICAL PRACTICE: Early treatment for high-risk prethreshold ROP does not adversely affect visual field extent clinically.

Entities:  

Mesh:

Year:  2011        PMID: 21320954     DOI: 10.1001/archophthalmol.2010.360

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  8 in total

1.  Clinical Management of Recurrent Retinopathy of Prematurity after Intravitreal Bevacizumab Monotherapy.

Authors:  Helen A Mintz-Hittner; Megan M Geloneck; Alice Z Chuang
Journal:  Ophthalmology       Date:  2016-05-27       Impact factor: 12.079

2.  Antecedents and correlates of visual field deficits in children born extremely preterm.

Authors:  Mari Holm; Michael E Msall; Jon Skranes; Olaf Dammann; Elizabeth Allred; Alan Leviton
Journal:  Eur J Paediatr Neurol       Date:  2014-10-12       Impact factor: 3.140

3.  Aggressive Posterior Retinopathy of Prematurity (APROP): LASER as the Primary Modality of Treatment.

Authors:  Shilpi H Narnaware; Prashant K Bawankule; Dhananjay Raje
Journal:  J Ophthalmic Vis Res       Date:  2021-07-29

Review 4.  The neural retina in retinopathy of prematurity.

Authors:  Ronald M Hansen; Anne Moskowitz; James D Akula; Anne B Fulton
Journal:  Prog Retin Eye Res       Date:  2016-09-23       Impact factor: 21.198

5.  Development of refractive error in individual children with regressed retinopathy of prematurity.

Authors:  Jingyun Wang; Xiaowei Ren; Li Shen; Susan E Yanni; Joel N Leffler; Eileen E Birch
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-09-05       Impact factor: 4.799

6.  Correspondence of retinal thinning and vasculopathy in mice with oxygen-induced retinopathy.

Authors:  Olachi J Mezu-Ndubuisi; Justin Wanek; Felix Y Chau; Pang-Yu Teng; Norman P Blair; Narsa M Reddy; J Usha Raj; Sekhar P Reddy; Mahnaz Shahidi
Journal:  Exp Eye Res       Date:  2014-04-02       Impact factor: 3.467

7.  Fzd4 Haploinsufficiency Delays Retinal Revascularization in the Mouse Model of Oxygen Induced Retinopathy.

Authors:  Michael H Ngo; Joanna Borowska-Fielding; Godfrey Heathcote; Sara Nejat; Melanie E Kelly; Christopher R McMaster; Johane M Robitaille
Journal:  PLoS One       Date:  2016-08-04       Impact factor: 3.240

8.  Retinopathy of Prematurity: Advances in the Screening and Treatment of Retinopathy of Prematurity Using a Single Center Approach.

Authors:  Audina M Berrocal; Kenneth C Fan; Hasenin Al-Khersan; Catherin I Negron; Timothy Murray
Journal:  Am J Ophthalmol       Date:  2021-07-21       Impact factor: 5.258

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.